STAT+

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the aftermath of FDA vote on MDMA, rising pharma layoffs, and more

Pharma Meghana Keshavan

STAT Plus: Psychedelics companies see FDA panel’s vote as a growth opportunity, not a roadblock

Hospitals Tara Bannow

STAT Plus: FTC loses its bid to block Novant’s hospital merger in North Carolina

Insurance Tara Bannow

STAT Plus: Appeals court overturns Sutter Health’s victory in $400 million antitrust case

Biotech Elaine Chen

STAT Plus: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about MDMA ‘no’ votes, a Gilead settlement, and more

Pharmalot Ed Silverman

STAT Plus: Student group that ranked med schools over industry conflicts votes to accept pharma funding

Pharmalot Ed Silverman

STAT Plus: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits

Health tech Mohana Ravindranath

STAT Plus: As Washington mulls new AI rules, startup leaders want a seat at the table

Biotech Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Takeaways: Winners, snoozers, the China question, and the art of cancer care

Pharmalot Ed Silverman

STAT Plus: U.S. drug shortages have reached a decade high and are lasting longer, too

Business Bob Herman

STAT Plus: Medicare Advantage plan’s quality ratings were incorrectly calculated by government, judge rules

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA meeting on MDMA, a new obesity pill, and more

Adam's Take Adam Feuerstein

STAT Plus: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug

Pharma Olivia Goldhill and Meghana Keshavan

STAT Plus: FDA advisory panel votes overwhelmingly against MDMA therapy for PTSD

Special Report Lizzy Lawrence

STAT Plus: How a device maker inundated pain patients with unwanted batteries and surprise bills

Biotech Jason Mast

STAT Plus: Illumina board agrees to spin off Grail, as divestment plans proceed

Biotech Matthew Herper, Adam Feuerstein, and Angus Chen

STAT Plus: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’

Pharmalot Ed Silverman

STAT Plus: Leading CRO to pay record fine for badly neglecting hundreds of beagles in breeding facility

Biotech Angus Chen

STAT Plus: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial

Health tech Lizzy Lawrence

STAT Plus: Becton Dickinson to buy Edwards patient monitoring unit for $4.2 billion

Health Care Inc. Bob Herman

STAT Plus: A short-lived Medicaid freakout sends insurers’ stocks diving

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Zantac lawsuits, worries over MDMA for PTSD, and more

Biotech Matthew Herper

STAT Plus: Delfi Diagnostics announces key data, study design for its liquid biopsy test

Biotech Elaine Chen

STAT Plus: Structure Therapeutics oral GLP-1 drug led to weight loss in two studies

Biotech Adam Feuerstein

STAT Plus: Agios drug reduces blood transfusions in patients with beta-thalassemia, study shows

Business Brittany Trang

STAT Plus: Elevance PBM’s president out as customers complain of prescription chaos

Hospitals Tara Bannow

STAT Plus: Physicians take Medicare Advantage to task for rural patients’ care gaps

Hospitals Bob Herman

STAT Plus: Which hospital systems will join Kaiser’s Risant next?